HOME >> MEDICINE >> NEWS
One drug, two targets

Targeted therapies are the new paradigm in cancer treatment and researchers at Fox Chase Cancer Center in Philadelphia are developing the second generation of these antibody-based drugs. Ongoing research at Fox Chase has demonstrated the ability of recombinantly engineered bispecific monoclonal antibodies to attack two separate targets on a single cancer cell. Most recently, the Fox Chase laboratory of Gregory P. Adams, Ph.D., has done preclinical tests of bispecific molecules carrying a radioactive isotope that can be used to detect or kill a tumor.

"What is unique is that these bispecific antibodies are expected to make the targeted tumor cells more sensitive to the radiation," said Adams, a researcher in the medical science division at Fox Chase Cancer Center. Adams presented his research today at the 94th annual meeting of the American Association for Cancer Research, July 11-14 in Washington, D.C.

Targeted cancer therapies work by attacking a single target on the surface of the cell, either delivering a toxic payload or directly causing it to stop multiplying or die. "Unfortunately, there is a lot of redundancy in cancer cells, making it difficult to kill a tumor with a single hit," Adams pointed out. "We wanted both to refine the tumor specificity of the antibodies and to increase their ability to kill the targeted cells.

"Our targets are members of the epidermal growth factor receptor family, a powerful group of signaling proteins that are found in many commonly occurring cancers. These receptors interact with each other to instruct cells to grow and resist the effects of many cancer cells. Simultaneously targeting pairs of these receptors can increase the specificity of tumor-cell targeting and block their signaling functions, thus making the cells more sensitive to treatment.

"Attaching radioisotopes to this molecule adds insult to injury and gives us a better chance to destroy cancer cells without attacking normal
'"/>


12-Jul-2003


Page: 1 2 3 4

Related medicine news :

1. Data shows new drug, rimonabant, helps smokers quit while limiting post cessation weight gain
2. Anti-epilepsy drug, topiramate, effective at preventing migraine headaches
3. Antiviral drug, valacyclovir, reduces genital herpes transmission
4. Hassle-free stroke prevention offered by new drug, Stanford researcher says
5. Common drug, given promptly, reduces incidence of post-traumatic stress disorder, small study finds
6. Non-drug, treatment for hypertension gets further physiological backing in AHAs Hypertension Primer
7. Substance found in sharks could lead to weight loss drug, research shows
8. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
9. NHS stop-smoking services are insufficient to deliver national smoking targets
10. Burning anxiety: New treatment targets smokers with panic disorder
11. Technology points to possible targets for epilepsy and Alzheimers drugs

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: One drug two targets

(Date:5/22/2013)... 2013, Paris, France: Results from a large ... question whether bivalirudin is superior to heparin ... similar 30-day mortality in patients with non-ST ... percutaneous coronary intervention (PCI)., European and US ... an alternative to unfractionated heparin plus GP ...
(Date:5/22/2013)... In the past decade, more than 500,000 ... with donated uniforms, shoes, balls and other equipment, thanks ... with manufacturers to provide youth with sporting goods. Now, ... in sports and fitness equipment over 10 years, as ... physical activity. , An inaugural donation of 500 ...
(Date:5/22/2013)... Kincardine, Ontario, CA (PRWEB) May 22, 2013 ... Meltdown Challenge, the fitness franchise Fit Body ... its 2nd Annual 1,000 lb. Meltdown Challenge starting on ... located at Davidson Centre 601 Durham Street, Kincardine, Ontario.     ... goal is to inspire and motivate local community residents ...
(Date:5/22/2013)... May 22, 2013 AvePoint ... solutions for social enterprise collaboration platforms, today announced ... firm based in Chicago, Ill. The agreement will ... and provide best-in-class solutions for SharePoint deployments, enabling ... , AvePoint’s DocAve Software Platform and ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Poor adherence ... in not only medical complications and death (some 125,000 ... drug non-adherence), but increased health-care costs. It’s been estimated ... admissions are related to poor medication adherence — a ... billion annually. , Indeed, so dire is the degree ...
Breaking Medicine News(10 mins):Health News:Registry questions superiority of bivalirudin over heparin 2Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 2Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 3Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2Health News:Kincardine Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 2Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 3Health News:Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance 2
(Date:5/21/2013)... Massachusetts , 21. Mai 2013 /PRNewswire/ ... („OSI"), die die Firmen OMNIlife science® Inc., Enztec ... zählt, hat zwei neue, erfahrene Mitglieder in ... , eine erfahrene Führungspersönlichkeit aus der ... David Johnson , anerkannter ...
(Date:5/21/2013)... May 21, 2013  LCA-Vision Inc. (NASDAQ: LCAV ... the Lasik Plus ® brand, announces that all nominees to ... at today,s annual meeting of stockholders.  These Directors are: ... President of Bahl & Gaynor Investment Counsel , ... , Edgar F. Heizer III , ...
(Date:5/21/2013)... 21, 2013  Decision Resources, one of ... for pharmaceutical and healthcare issues, finds that ... key efficacy endpoints, including overall survival and ... influence over surveyed U.S. and European oncologists, ... HER2-negative breast cancer. The two novel emerging ...
Breaking Medicine Technology:Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 2Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 3LCA-Vision Reports on Annual Meeting of Stockholders 2LCA-Vision Reports on Annual Meeting of Stockholders 3LCA-Vision Reports on Annual Meeting of Stockholders 4Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer 2
Cached News: